Interviews with Pharma and Biotech Global Leaders
Refine search
Biotechnology
The recent news flow at Dewpoint Therapeutics—the firm making condensate biology a clinical reality—has been striking in its volume and significance. 10 March 2026
Pharmaceutical
The days of flying under the radar are over for Isotope Technologies Munich (ITM), a privately-held German radiopharmaceutical company. 25 February 2026
Pharmaceutical
Chugai starts 2026 having just celebrated its first century, just as Nicolas Henriot completes his first year leading Chugai Pharma Europe. It is a moment of symmetry that the new general manager says has sharpened the region’s sense of purpose, balancing a century of scientific heritage with a need for agility in a fast-moving European market. 12 February 2026
Pharmaceutical
As global pharma companies seek resilient supply chains, competitive manufacturing bases and access to emerging markets, Egypt is increasingly appearing on investors’ radars. The Pharma Letter spoke to Dr Ahmed Badr Eldeen, plant manager at Zeta Pharma Egypt, to understand what international investors
truly look for when assessing opportunities in the Egyptian pharmaceutical
sector. 11 February 2026
Biotechnology
It is becoming evident that German oncology start-up CatalYm has a highly promising asset on its hands in the shape of visugromab, a first-in-class anti-growth differentiation factor-15 (GDF-15) antibody. 29 January 2026
Pharmaceutical
Ossama Anter Abo Arab, chief executive of MultiCare Egypt for Pharmaceutical Industries, talks with The Pharma Letter about pharmaceutical growth in Egypt. 26 January 2026
Pharmaceutical
In an industry where many companies claim to be reinventing the wheel, it is rare to find one that is truly doing something different—and winning recognition from big pharma for doing so. 26 January 2026
Pharmaceutical
Australian biotech Neurizon Therapeutics is setting out to redefine how neurodegenerative diseases are treated, positioning itself as a rare-disease innovator in a space long starved of effective therapies. 23 January 2026
Biosimilars
This month, Samsung Bioepis announced the European launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. 29 December 2025
Biotechnology
CSL presented new HOPE-B Phase III data confirming the five-year durability of Hemgenix (etranacogene dezaparvovec), the only gene therapy for haemophilia B, at the American Society of Hematology (ASH) Annual Meeting earlier this month. 21 December 2025
Pharmaceutical
As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, the company’s new office in Stockley Park, London, is as impressive as it gets. 11 December 2025
Pharmaceutical
New FIBRONEER results were presented by Boehringer Ingelheim at this year’s European Respiratory Society (ERS) International Congress that bring a new dimension to the nerandomilast Phase III data story in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). 21 November 2025
Pharmaceutical
Established by ADQ, an active sovereign investor focused on critical infrastructure and global supply chains, Arcera is redefining what it means to build a global healthcare company from the region. In an industry often shaped by short-term market cycles, Arcera combines the independence of a privately held company with the scale and ambition of a global player, backed by a clear mandate to expand into new markets and strengthen healthcare resilience. 17 November 2025
Pharmaceutical
Swiss pharma giant Roche could be among the best-placed drugmakers to tackle two of today’s biggest challenges in global healthcare, according to Teresa Graham, chief executive of its Pharmaceuticals division. 12 November 2025
Biotechnology
Germany-based Immatics has this month announced updated clinical data from its PRAME-directed TCR T-cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), in 16 patients with metastatic uveal melanoma. 3 November 2025
Pharmaceutical
In May of this year, AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate)—already licensed to treat chronic obstructive pulmonary disease (COPD) in adults—was approved for use in the UK with an innovative, next-generation propellant with near-zero global warming potential (GWP). 23 September 2025
Pharmaceutical
An Executive Q&A with Jon Congleton, chief executive of fast-moving biopharma company Mineralys Therapeutics. 2 September 2025
Biosimilars
After nearly 27 years as a division of Swiss giant Novartis, generics and biosimilars specialist Sandoz went its own way in October 2023. 2 August 2025
Pharmaceutical
Data presented on the EURneffy/neffy adrenaline (epinephrine) nasal spray at the European Academy of Allergy & Clinical Immunology Congress last month highlights a comparable clinical pharmacological response to intramuscular adrenaline injection, despite congestion associated with allergic rhinitis. 12 July 2025
Pharmaceutical
Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic. 23 June 2025
Biotechnology
The recent news flow at Dewpoint Therapeutics—the firm making condensate biology a clinical reality—has been striking in its volume and significance. 10 March 2026
Pharmaceutical
The days of flying under the radar are over for Isotope Technologies Munich (ITM), a privately-held German radiopharmaceutical company. 25 February 2026
Pharmaceutical
Chugai starts 2026 having just celebrated its first century, just as Nicolas Henriot completes his first year leading Chugai Pharma Europe. It is a moment of symmetry that the new general manager says has sharpened the region’s sense of purpose, balancing a century of scientific heritage with a need for agility in a fast-moving European market. 12 February 2026
Pharmaceutical
As global pharma companies seek resilient supply chains, competitive manufacturing bases and access to emerging markets, Egypt is increasingly appearing on investors’ radars. The Pharma Letter spoke to Dr Ahmed Badr Eldeen, plant manager at Zeta Pharma Egypt, to understand what international investors
truly look for when assessing opportunities in the Egyptian pharmaceutical
sector. 11 February 2026
Biotechnology
It is becoming evident that German oncology start-up CatalYm has a highly promising asset on its hands in the shape of visugromab, a first-in-class anti-growth differentiation factor-15 (GDF-15) antibody. 29 January 2026
Pharmaceutical
Ossama Anter Abo Arab, chief executive of MultiCare Egypt for Pharmaceutical Industries, talks with The Pharma Letter about pharmaceutical growth in Egypt. 26 January 2026
Pharmaceutical
In an industry where many companies claim to be reinventing the wheel, it is rare to find one that is truly doing something different—and winning recognition from big pharma for doing so. 26 January 2026
Pharmaceutical
Australian biotech Neurizon Therapeutics is setting out to redefine how neurodegenerative diseases are treated, positioning itself as a rare-disease innovator in a space long starved of effective therapies. 23 January 2026
Biosimilars
This month, Samsung Bioepis announced the European launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. 29 December 2025
Biotechnology
CSL presented new HOPE-B Phase III data confirming the five-year durability of Hemgenix (etranacogene dezaparvovec), the only gene therapy for haemophilia B, at the American Society of Hematology (ASH) Annual Meeting earlier this month. 21 December 2025
Pharmaceutical
As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, the company’s new office in Stockley Park, London, is as impressive as it gets. 11 December 2025
Pharmaceutical
New FIBRONEER results were presented by Boehringer Ingelheim at this year’s European Respiratory Society (ERS) International Congress that bring a new dimension to the nerandomilast Phase III data story in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). 21 November 2025
Pharmaceutical
Established by ADQ, an active sovereign investor focused on critical infrastructure and global supply chains, Arcera is redefining what it means to build a global healthcare company from the region. In an industry often shaped by short-term market cycles, Arcera combines the independence of a privately held company with the scale and ambition of a global player, backed by a clear mandate to expand into new markets and strengthen healthcare resilience. 17 November 2025
Pharmaceutical
Swiss pharma giant Roche could be among the best-placed drugmakers to tackle two of today’s biggest challenges in global healthcare, according to Teresa Graham, chief executive of its Pharmaceuticals division. 12 November 2025
Biotechnology
Germany-based Immatics has this month announced updated clinical data from its PRAME-directed TCR T-cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), in 16 patients with metastatic uveal melanoma. 3 November 2025
Pharmaceutical
In May of this year, AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate)—already licensed to treat chronic obstructive pulmonary disease (COPD) in adults—was approved for use in the UK with an innovative, next-generation propellant with near-zero global warming potential (GWP). 23 September 2025
Pharmaceutical
An Executive Q&A with Jon Congleton, chief executive of fast-moving biopharma company Mineralys Therapeutics. 2 September 2025
Biosimilars
After nearly 27 years as a division of Swiss giant Novartis, generics and biosimilars specialist Sandoz went its own way in October 2023. 2 August 2025
Pharmaceutical
Data presented on the EURneffy/neffy adrenaline (epinephrine) nasal spray at the European Academy of Allergy & Clinical Immunology Congress last month highlights a comparable clinical pharmacological response to intramuscular adrenaline injection, despite congestion associated with allergic rhinitis. 12 July 2025
Pharmaceutical
Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic. 23 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze